<code id='8501F18B80'></code><style id='8501F18B80'></style>
    • <acronym id='8501F18B80'></acronym>
      <center id='8501F18B80'><center id='8501F18B80'><tfoot id='8501F18B80'></tfoot></center><abbr id='8501F18B80'><dir id='8501F18B80'><tfoot id='8501F18B80'></tfoot><noframes id='8501F18B80'>

    • <optgroup id='8501F18B80'><strike id='8501F18B80'><sup id='8501F18B80'></sup></strike><code id='8501F18B80'></code></optgroup>
        1. <b id='8501F18B80'><label id='8501F18B80'><select id='8501F18B80'><dt id='8501F18B80'><span id='8501F18B80'></span></dt></select></label></b><u id='8501F18B80'></u>
          <i id='8501F18B80'><strike id='8501F18B80'><tt id='8501F18B80'><pre id='8501F18B80'></pre></tt></strike></i>

          Home / explore / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:772

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In